Nitya Raj, MD
Hematology & Oncology · New York, NYNPI 1942526017
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,740 of the $26,803 with a category attached, or 77.4%. 6 manufacturers reported payments, led by Boehringer Ingelheim at 48.9% of the total. 2025 is the largest year on record at $13,319, more than ten times the $12 reported in 2020.
Across 24 payments — averaging $1116.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$13K
- Exelixis Inc.$6K
- Ipsen Biopharmaceuticals, Inc$4K
- HRA Pharma RARE Diseases$2K
- Progenics Pharmaceuticals, Inc.$2K
- Stimwave Technologies Incorporated$12
Across 4 payments — averaging $14,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$35K
- Corcept Therapeutics$23K
What the payments were for
- Consulting fees$20,74077%
- Speaking & faculty fees$4,29016%
- Travel & lodging$1,1384%
- Food & beverage$6352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $13,106 |
| Exelixis Inc. | 8 | $6,415 |
| Ipsen Biopharmaceuticals, Inc | 2 | $3,520 |
| HRA Pharma RARE Diseases | 1 | $2,000 |
| Progenics Pharmaceuticals, Inc. | 2 | $1,750 |
| Stimwave Technologies Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$6,285
- SOMATULINE DEPOT$3,520
- Lysodren$2,000
- AZEDRA$1,750
How this compares
$26,803 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 15 | $41,007 |
| Ursodiol | 19 | $1,323 |
| Ondansetron Hcl | 47 | $1,317 |
| Pantoprazole Sodium | 19 | $221 |
| Oxycodone Hcl | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.